30 closest matches · ranked by relevance
Diffuse Intrinsic Pontine Glioma
Primary: Two Year Survival of Pediatric Patients With Diffuse Pontine Gliomas — 14.29 Percentage of patients
Glial Cell Tumors · Malignant Gliomas · Glioblastoma Multiforme
Primary: 1-year Event Free Survival (EFS) — 12; 24 percentage of participants — p=< 0.05
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Brain and Central Nervous System Tumors
Primary: Percentage of Participants With an Objective Response (Complete Response or Partial Response) — 4; 0 Percent of Participants
Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in the Phase I Component With Dose-limiting Toxicities (DLTs) Observed During the First 8 Weeks (Courses 1 and 2) of Tipifarnib Therapy — 0; 1; 4…
Brainstem Glioma
Primary: Progression-free Survival — 4.9 Months
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Glioblastoma Multiforme · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Number of Patients Who Experienced Dose-limiting Toxicities (DLTs) — 3 Participants
Brain Tumor · Central Nervous System Tumor
Primary: Short Term Feasibility Success — 25 participants
Brain Tumor · Central Nervous System Tumor
Primary: Marginal-failure Rate — 0 percentage of failure rate
Brain Cancer
Primary: Number of Participants With High-grade Astrocytoma and Diffuse Pontine Tumors Achieving One Year Progression Free Survival. — 5; 6 Participants
Glioma
Primary: Maximum Tolerated Dose (MTD) of Capecitabine. — 650 milligrams
Visual Pathway Glioma
Primary: Number of Participants With Objective Response — 2; 2; 3; 1 Participants
High Grade Glioma
Primary: Event-Free Survival (EFS) as Assessed by the Central Radiology Review Committee (CRRC) — 11.79; 8.21 months — p=0.1292
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Childhood Brain Tumors
Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Low-grade Glioma
Primary: Progression-free Survival — 23.1 percentage
Brain Tumors
Primary: Event-free Survival (EFS)
Juvenile Pilocytic Astrocytomas · Optic Pathway Gliomas
Primary: Number of Children Responding to Treatment — 0; 0; 5 Participants
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Low Grade Astrocytomas
Primary: Number of Participants With Objective Response — 4; 1; 4; 0 Participants
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) of Vorinostat — 230 mg/m^2
Brain Tumor · Low Grade Glioma · Astrocytoma
Primary: Endocrine Dysfunction — 14.5; 20.2 percentage of participants
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Childhood Cerebral Anaplastic Astrocytoma · Childhood Oligodendroglioma · Childhood Spinal Cord Neoplasm
Primary: Objective Response Rate Sustained for ≥ 8 Weeks — 0; 0; 0; 0 participants
Untreated Childhood Anaplastic Astrocytoma · Untreated Childhood Anaplastic Oligodendroglioma · Untreated Childhood Brain Stem Glioma
Primary: Number of Participants in Phase I Stratum 1A With Dose-limiting Toxicities (DLT) Observed During the First 8 Weeks of Gefitinib Therapy — 2; 0; 1 Participants
Glioma · Medulloblastoma
Primary: Percentage of Participants With Objective Response of Complete Response or Partial Response — 32.6; 0 percentage of participants